---
title: Associate Professor Danny Soon
permalink: /biography/management-team/a-prof-danny-soon/
description: ""
third_nav_title: Management Team
variant: tiptap
---
<h3>A/Prof Danny Soon</h3>
<div class="isomer-image-wrapper">
<img style="width: 40%;" height="auto" width="100%" alt="" src="/images/Newsroom &amp; Events/In The News And Media Releases/Isomer_Dr_Danny_Soon.jpg">
</div>
<h4>Affiliations</h4>
<p>Chief Executive Officer, Consortium for Clinical Research and Innovation,
Singapore</p>
<p>Executive Director, Singapore Clinical Research Institute</p>
<p>Senior Advisor, Advanced Cell Therapy and Research Institute, Singapore</p>
<h4>Profile</h4>
<p>Assoc. Prof. Danny Soon is Chief Executive Officer at the Consortium for
Clinical Research and Innovation, Singapore (CRIS) and concurrent Executive
Director at the Singapore Clinical Research Institute (SCRI). Danny currently
serves as Senior Advisor, Advanced Cell Therapy and Research Institute,
Singapore (ACTRIS) effective from 1 March 2025 to 31 August 2025. He was
previously the Interim Executive Director of ACTRIS from 1 September 2022
to 28 February 2025. As the inaugural CEO of CRIS, Danny has the responsibility
of bringing together six research programmes and platforms under the auspices
of CRIS, promulgating synergies and strategies, building corporate functions
to service the entire entity.</p>
<p>A/Prof Soon was previously the Executive Director of Biomedical Research
Council (BMRC) in A*STAR. His team in BMRC was responsible for incepting
and coordinating efforts and programmes in drug development, precision
medicine, medical technology and biomanufacturing. A/Prof Soon also held
the role of founding and Acting CEO of the Experimental Biotherapeutics
Centre.&nbsp;</p>
<p>Danny has long experience in drug development, having worked at Eli Lilly
and Company for 15 years, where he headed up the Lilly-NUS Centre for Clinical
Pharmacology (LNUS). As the Managing Director and Principal Investigator,
Danny had responsibility and oversight for all clinical Phase 1 studies
conducted and operations in the unit. Studies conducted included first-in-human
studies, biomarker development work, human physiology investigations and
pivotal registration PK studies, in neuroscience, diabetes, musculoskeletal
and cardiovascular therapeutic areas.</p>
<p>
<br>
</p>
<p></p>